Phase 3Completed
MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H5: MP0420)
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
- Enrollment
- 485 enrolled
- Conditions
- COVID-19
- Interventions
- MP0420; Placebo; Remdesivir
- Ages
- adults, older adults
- Registry
- NCT05780463
Full record on ClinicalTrials.gov
From the registry
This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H5.
Primary outcomes
- Number of Participants With Sustained Recovery
- Number of Participants With an Ordinal Outcome on Day 5
History
Results first posted
Last registry update
Study completion
Registered
Primary completion
Started